Scilex Holding Company

NASDAQ:SCLX

6.36

+0.12 (+1.92%)

4:26:52 PM EDT: $6.46 +0.10 (+1.57%)

Market Cap (Intraday)	45.06M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	2.05

See more stats

Estimates Current Quarter

Revenue	$26.25 Million
Adjusted EPS	-$0.91

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Scilex Holding Company Stock, NASDAQ:SCLX

960 San Antonio Road, 1 Habourfront Avenue, Palo Alto, California 94303

United States of America

Phone: +1.650.516.4310

Number of Employees: 105

http://www.scilexholding.com

Description

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTlido, a prescription lidocaine topical product approved by the FDA for the relief of neuropathic pain associated with PHN, which is a form of post-shingles nerve pain, and e GLOPERBA oral solutions, an FDA-approved prophylactic treatment for painful gout flares in adults. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.